Apo Kuipers SRL
Apo Kuipers reported total assets of 146,357 € at the end of the 2025 financial year (annual accounts filed with the NBB on 22 Jun 2026).
The score of Apo Kuipers shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +33 % Total assets +26 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Apo Kuipers's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 13,000 € | ||||
| Equity | 142,208 € | ||||
| Cash | 93,434 € | ||||
| EBITDA | 21,731 € | ||||
| Total assets | 146,357 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 22 Jun 2026
- Year ended 31 Dec 2024filed on 01 Jul 2025
- Year ended 31 Dec 2023filed on 12 Jul 2024
- Year ended 31 Dec 2022filed on 22 Aug 2023
- Year ended 31 Dec 2021filed on 30 Aug 2022
Apo Kuipers's financial analysis
- Solvency97.2%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Apo Kuipers
Apo Kuipers's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0642.552.348
- VAT number
- BE0642552348
- Peppol
- Registered · 0208:0642552348 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 01 Nov 2015
- Registered office
- 3211 Lubbeek
- Latest accounts
- 2025 · filed on 22 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Apo Kuipers (SRL) has been based in Lubbeek since 2015, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 13,000 € and equity of 142,208 €; its revenue is not published. Its solvency stands at 97.2%, above the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Apo Kuipers
Companies in the same business, of comparable size and area, outside its group.
- Vroome Pharma Management Retail sale of pharmaceutical products Antwerp · balance sheet 229,894 €
- Eliam Retail sale of pharmaceutical products Hasselt · balance sheet 122,187 €
- Apotheker Delcourt Retail sale of pharmaceutical products Lennik · balance sheet 171,416 €
- North Flow Retail sale of pharmaceutical products Antwerp · balance sheet 303,640 €
- Pribe Retail sale of pharmaceutical products Roeselare · balance sheet 123,987 €
- Lidefarma Retail sale of pharmaceutical products Lierde · balance sheet 495,027 €
- JPMA Retail sale of pharmaceutical products Ottignies-Louvain-la-Neuve · balance sheet 295,815 €
- ENNC Retail sale of pharmaceutical products Oud-Heverlee · balance sheet 149,458 €
Frequently asked questions about Apo Kuipers
What is the revenue of Apo Kuipers?
Apo Kuipers files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Apo Kuipers?
In Belgium, the VAT number is the company number prefixed with BE: BE0642552348 for Apo Kuipers, if the company is VAT-registered. Its company number (CBE) is 0642.552.348.
Where is the registered office of Apo Kuipers?
According to the CBE register, the registered office of Apo Kuipers is in 3211 Lubbeek.
What is the equity of Apo Kuipers?
At the close of the 2025 financial year, the equity of Apo Kuipers amounts to 142,208 €, a solvency of 97.2% of total assets.
Who manages Apo Kuipers?
The register lists 1 active mandates at Apo Kuipers. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Apo Kuipers
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →